Chris:
I haven't owned BGEN for about 10 years, so this doesn't hurt the wallet. However, I'm very bummed. The question is, will IDPH also take it on the chin, or is there already evidence that it's an antibody-specific issue (if there's an issue at all).
The competitive projects using MAbs are easy to find, but..... I've sort of just filed any reports of projects looking downstream, small molecule intracellular stuff.
If it's an epitope-specific issue, BGEN may still be in the driver's seat. However, one would also think that another company could then sneak in with some new claims.
Bummed, bummed, bummed. Hope this is just a hiccup for BGEN, and virtually no impediment for IDPH.
Rick |
